AllSci News
Cambium secures NCI funding to advance VIP checkpoint therapy for AML
Cambium Oncology LLC, an Atlanta-based biotech, has received a USD 1.05 million SBIR fast-track grant from the National Cancer Institute to advance...
NIH backs overdose-limiting oxycodone prodrug with USD 5.28m award
Ensysce Biosciences (La Jolla, California) has received a USD 5.28 million U01 cooperative agreement from the National Institute on Drug Abuse to continue...
Jacaranda takes SBIR Phase II grant for noise-induced hearing loss therapeutics
Jacaranda Bioscience, Inc., a San Francisco-based biotech, has received a USD 1.44 million SBIR Phase II award from the National Institute on Deafness and...
Alpha DaRT shows early signs of boosting pembrolizumab responses in head and neck cancer
Alpha Tau Medical Ltd. (Jerusalem, Israel) (Nasdaq: DRTS, DRTSW) reported that Alpha DaRT, its intratumoral alpha-emitting radiotherapy device, produced a...
Imunon's IL-12 gene therapy shows early safety signal while reducing ovarian cancer residual disease
Imunon, Inc. (Lawrenceville, New Jersey; Nasdaq: IMNN) reported preliminary Phase II data for IMNN-001 in newly diagnosed advanced ovarian cancer, drawn...
TYK Medicines secures USD 408 million from Qilu for China lung cancer drug rights
TYK Medicines, Inc. (HKEX: 2410), a Huzhou, China-based oncology drug developer, has struck a license and collaboration agreement with Qilu Pharmaceutical...
Celldex ends barzolvolimab prurigo nodularis study after Phase II miss
Celldex Therapeutics (Hampton, New Jersey; Nasdaq: CLDX) reported topline results from a Phase II study of subcutaneous barzolvolimab in prurigo nodularis,...
Roche's USD 700m deal for Nurix's BTK degrader clears antitrust review
Nurix Therapeutics (Nasdaq: NRIX) said its global collaboration with Roche to co-develop and co-commercialize bexobrutideg (NX-5948) has closed following...
Estrigenix secures seed financing to advance Marquette- and UWM-sourced estrogen receptor-beta platform
Milwaukee-based Estrigenix Therapeutics, a biotechnology company developing selective estrogen receptor-beta (ERβ) therapeutics, has announced the first...
Novartis Q2'26: AOC FDA filing and FSHD biomarker progress as H2 catalyst slate builds
Novartis AG (NYSE: NVS) held its Novartis Q2 2026 earnings call on July 21, 2026, during which executives detailed the company's first FDA submission for an...
Curatix secures NIAID support for drug-resistant fungal infection adjuvants
The Small Business Innovation Research (SBIR) mechanism at the National Institute of Allergy and Infectious Diseases (NIAID) has awarded a USD 1.0 million...
Nuvation expands safusidenib program into post-vorasidenib IDH1-mutant glioma
Nuvation Bio Inc. (NYSE: NUVB) reported updated long-term data on Monday from the safusidenib clinical trial in IDH1-mutant glioma, alongside plans to...
Kolon's TG-C Phase III failure slows cell therapy push into knee osteoarthritis
Kolon TissueGene's first pivotal test of a cell and gene therapy for knee osteoarthritis has come back negative, complicating a development program that...
Lupin spins out PRMT5 and SOS1 oncology programs into equity-backed Kaveri
Lupin Limited (BSE: 500257, NSE: LUPIN) has moved two clinical-stage oncology assets off its own balance sheet and into a newly formed company, in a...
Engitix taps Lonza's ADC platform to target cancer through extracellular matrix discovery
Basel, Switzerland-based Lonza (SIX: LONN) has granted London-based Engitix Therapeutics a single-target license to its antibody-drug conjugate technology...
The AllSci Brief
Systematic R&D and deal news. Daily.